- Home
- ACAD vs AKRO Comparison
ACAD vs AKRO Comparison
Compare ACAD & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- AKRO
- Stock Information
- Founded
- ACAD 1993
- AKRO 2017
- Country
- ACAD United States
- AKRO United States
- Employees
- ACAD N/A
- AKRO N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ACAD Health Care
- AKRO Health Care
- Exchange
- ACAD Nasdaq
- AKRO Nasdaq
- Market Cap
- ACAD 4.3B
- AKRO 3.6B
- IPO Year
- ACAD 2004
- AKRO 2019
- Fundamental
- Price
- ACAD $24.67
- AKRO $42.85
- Analyst Decision
- ACAD Buy
- AKRO Strong Buy
- Analyst Count
- ACAD 21
- AKRO 8
- Target Price
- ACAD $29.30
- AKRO $80.38
- AVG Volume (30 Days)
- ACAD 1.8M
- AKRO 871.2K
- Earning Date
- ACAD 11-05-2025
- AKRO 11-07-2025
- Dividend Yield
- ACAD N/A
- AKRO N/A
- EPS Growth
- ACAD 615.00
- AKRO N/A
- EPS
- ACAD 1.33
- AKRO N/A
- Revenue
- ACAD $1,018,885,000.00
- AKRO N/A
- Revenue This Year
- ACAD $14.01
- AKRO N/A
- Revenue Next Year
- ACAD $11.72
- AKRO N/A
- P/E Ratio
- ACAD $18.55
- AKRO N/A
- Revenue Growth
- ACAD 14.41
- AKRO N/A
- 52 Week Low
- ACAD $13.40
- AKRO $21.34
- 52 Week High
- ACAD $26.65
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ACAD 49.69
- AKRO 35.10
- Support Level
- ACAD $23.34
- AKRO $42.56
- Resistance Level
- ACAD $25.90
- AKRO $45.44
- Average True Range (ATR)
- ACAD 0.78
- AKRO 1.77
- MACD
- ACAD -0.28
- AKRO -0.21
- Stochastic Oscillator
- ACAD 40.18
- AKRO 14.90
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.